...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: How & who comes up with valuations?
Reply New Message
Prev Message Back To Forum Threaded View Next Message

I believe the Alpine drug passed Phase 11. Phase 111 is scheduled for H2/2024.

I'm not aware that Zenith has proof of success. ZEN-3694 to my understanding passed a Phase 1 safety profile, for mCRPC. (reference Oct 26, 2023 AGM)

 

Koo

1 Recommendations
Reply New Message
Prev Message Back To Forum Threaded View Next Message
Share
Share
New Message
Please login to post a reply